The Impact of Elevated Serum Urate Levels and Tophi on HRQOL and Daily Functioning in Patients with Uncontrolled Gout

• APLAR •
• 31 October, 2026 •
• •

Efficacy of Pozdeutinurad (AR882) in Treatment Naïve and Uncontrolled Gout or Tophaceous Gout Patients in Asia-Pacific Patients

Robert Keenan, James Cheng-Chung Wei, Zancong Shen, Wen Wei, Sarah Morris

• APLAR •
• 31 October, 2026 •
• •

Supratherapeutic Doses of Pozdeutinurad: Pharmacokinetic and Pharmacodynamic Assessment in Healthy Subject Volunteers

Zancong Shen, Andrea Clouser Roche, Janina Rivera, Jia Hu, Rongzi Yan, Shunqi Yan, Robert Keenan

• ISPOR •
• 18 May, 2026 •
• •

Association Between Clinical Manifestations of Gout and Patient Reported Outcome Measures: Results of a Real-World Survey in the United States

Andrew Sulich, Menaka Bhor, James Hawthorne, Emily Goddard, Molly Edwards, Alastair Hinds, Ted Mikuls

Available materials

• NKF •
• 7 May, 2026 •
• •

Nanoencapsulated Sirolimus Plus Pegadricase (NASP) Provides a Sustained 48-Week Response, Reducing Serum Uric Acid and Preserving Renal Function in Patients With Uncontrolled Gout (UG) and Stage 3 Chronic Kidney Disease

Nissreen Elfadawy, Rehan Azeem, Pirooz Parsa, Ben Peace, Yasir A. Qazi

Available materials